Replies to post #82943 on Biotech Values

[genisi]

NSCLC Biomarker

The reuters report didn't say that but the genetic test will probably look for patients who are positive for the Anaplastic Lymphoma Kinase (ALK) fusion gene (variants of EML4-ALK fusion gene).

http://clincancerres.aacrjournals.org/cgi/content/full/14/13/4275?maxtoshow=&HITS=100&hits=100&RESULTFORMAT=&titleabstract=kinase&searchid=1&FIRSTINDEX=0&fdate=//&resourcetype=HWCIT

[jbog]

Dew, Regarding the NSCLC Biomarker

I noticed that Pfizer has a presentation detailing an phase I trial using PF- 02341066 [oral c-met and ALK inhibitor] at ESMO next month. It's being presented in the "Presidential, Best Of 2009" group. Bipar's BSI-201 [PARP1] inhibitor is in the same group.

[genisi]

NSCLC predictive biomarker

About 6 to 7 percent of non-small cell lung cancer patients have the rearrangement

The prevalence of the EML4-ALK fusion oncogene is higher among lung adenocarcinomas, in non or light smokers and in EGFR, KRAS-negative cases.